1. Medtech Insight
  2. >>Device Area

Abbott’s Plan For DBS Depression Therapy Wins FDA’s Breakthrough Designation

 
• By Reed Miller

Abbott continued St. Jude Medical’s prior research on deep brain stimulation for treating depression and has advanced the technology far enough that the US FDA now believes it could be a breakthrough treatment for treatment-resistant depression.

depression cartoon 2100803380 1200.jpg
• Source: Shutterstock

[Editor's Note: This article was updated on 20 July to correct the information about the termination of the BROADEN trial. St. Jude Medical, not the US FDA, chose to terminate the trial following the futility analysis, according to Abbott.]

Abbott is adapting its deep-brain stimulation (DBS) technology to treat chronic depression in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

More from Device Area